IP Library › Granted Patent US 10,858,452
Granted Patent B2
US 10,858,452 · App. 15/754,664 · Granted Dec 8, 2020

Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases

Inventors: Erwan Mortier (Nantes, FR); Dihia Meghnem (Nantes, FR); Sebastien Morisseau (Nantes, FR); Yannick Jacques (Nantes, FR)
Assignees: Insitut National de la Sante et de la Recherche Medicale (INSERM); Universite de Nantes; Universite d'Angers; Centre National de la Recherche Scientifique; Centre Hospitalier Universitaire de Nantes
C07K19/00A61K39/39533C07K14/5443C07K14/7155C07K16/2866C12N15/62A61K38/1774A61K38/1793A61K38/2086A61P37/06C07K2317/52C07K2317/76C07K2319/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,858,452
App. No.
15/754,664
Granted
Dec 8, 2020
Kind
B2
Abstract

The present invention relates to specific interleukin-15 (IL-15) antagonist polypeptides and uses thereof for the treatment of inflammatory and auto-immune diseases. In particular, the present invention relates to a specific interleukin-15 (IL-15) antagonist polypeptide comprising i) a IL15-Ralpha sushi-containing polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence of SEQ ID NO:1 ii) a linker and iii) an IL-polypeptide comprising the amino acid sequence having at least at least 80% of identity with the amino acid sequence of SEQ ID NO:4 provided that the glutamine (Q) residue at position 108 is mutated.

Claims (7)

1. A polypeptide comprising the polypeptide of SEQ ID NO:5 or SEQ ID NO:6, having

an IL15-Ralpha sushi-containing polypeptide,

a linker, and

an IL-15 polypeptide wherein the residue at position 108 in the IL-15 polypeptide is not a glutamine (Q).

2. The polypeptide of claim 1 , which is fused to an immunoglobulin domain.

3. The polypeptide of claim 2 , wherein the immunoglobulin domain is an immunoglobulin constant domain (Fc region).

4. A pharmaceutical composition comprising the polypeptide of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2018
From: MORTIER, ERWAN; MEGHNEM, DIHIA; MORISSEAU, SEBASTIEN; JACQUES, YANNICK
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE DE NANTES; UNIVERSITE D'ANGERS; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
Reel/Frame 045016/0076 →
Priority Claims (1)
EP 15306418 · Sep 16, 2015 · regional
Continuity (1)
Related Publication 20180258174A1 · Sep 13, 2018
Cited By (2)
US 12,459,980 US 12,600,762